Company / Gross Margin
Processa Pharmaceuticals, Inc. Gross Margin History
FY2013-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
-11.0%
FY2016
5-year range
-11.0% / 39.8%
FY2013-FY2016
Trend
-129.1%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from 39.8% to -11.0% over the past 2 years.
Based on SEC 10-K filings.
-11.0% in FY2016 with a 3-year CAGR of -41.6%.
Declined from 39.8% to -11.0% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- -41.6pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2016, gross margin decreased 129.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | - | - |
| FY2021 | - | - |
| FY2016 | -11.0% | -129.1% |
| FY2015 | 37.7% | -5.4% |
| FY2014 | 39.8% | +30.0% |
| FY2013 | 30.6% | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026